Coherus Biosciences (CHRS) AI Stock Analysis

• Market Cap: $86.15M
• Dividend Yield: N/A
• Average Volume (3M): 1.19M
• Price to Earnings (P/E): 5.5
• Beta (1Y): 1.44
• Revenue Growth: -34.58%
• EPS Growth: -62.19%
• Country: US
• Employees: 228
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 115,933,270
• 10 Day Avg. Volume: 1,322,358
• 30 Day Avg. Volume: 1,187,436
• PEG Ratio: -0.51
• Price to Book (P/B): -4.47
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.53
• Enterprise Value/Market Cap: 11.87
• Enterprise Value/Revenue: 0.95
• Enterprise Value/Gross Profit: 9.32
• Enterprise Value/Ebitda: -2.40
• 1Y Price Target: $4.03
• Price Target Upside: 430.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 45 Neutral
• Price Target: $1.00 ▲(31.58%Upside)

The overall stock score reflects significant financial challenges, including declining revenues and high leverage, which are major risk factors. While there are promising growth prospects from the oncology focus and recent corporate events, the technical analysis indicates bearish trends. The valuation remains unattractive due to negative earnings and lack of dividends. Strategic initiatives and cost-saving measures offer some positive outlook, but financial stability and market penetration remain crucial.

Positive Factors

Financial Stability

Once the Udenyca divestment is reflected in Q2, Coherus expects to have ~$250MM in cash on hand, providing about two years of operational runway.

Product Adoption

The National Comprehensive Cancer Network (NCCN) revised guidelines include Loqtorzi as the preferred regimen.

Strategic Transition

Coherus has made significant positive progress as it has completed its transition to a novel oncology company, including what is considered an attractive sale of its biosimilar business, allowing the company to extinguish its debt and provide funding for the next ~18 months as it executes on driving Loqtorzi sales.

Negative Factors

Earnings Performance

Q1 net revenue of $40MM was below our $55MM forecast.

Market Competition

Checkpoint inhibitors remain a crowded space dominated by some of the largest players in pharma, and Coherus' pipeline assets to pair with the PD1 are relatively early stage.

Revenue Growth

Limited visibility exists on the growth trajectory in NPC, and more mature data sets for the combinations are likely 2026 events, leading to a Hold rating as clarity is awaited on NPC revenue materialization.

Coherus Biosciences Business Overview & Revenue Model

Company Description

Coherus BioSciences, Inc. (CHRS) is a biopharmaceutical company focused on the development, commercialization, and delivery of high-quality biosimilar and innovative biologic medicines. Headquartered in Redwood City, California, Coherus aims to increase access to important therapeutics and reduce healthcare costs. The company’s portfolio includes biosimilar products for oncology and immunology, with a strategic emphasis on developing treatments that address unmet medical needs.

How the Company Makes Money

Coherus BioSciences generates revenue primarily through the sale of its biosimilar products. The company capitalizes on the growing demand for cost-effective biologic therapies by offering biosimilars that are therapeutically equivalent and more affordable than original biologic drugs. Key revenue streams include sales of their biosimilar to pegfilgrastim, which is used to decrease the chance of infection in cancer patients undergoing chemotherapy, and other pipeline biosimilars. Coherus also enters into strategic partnerships and licensing agreements to enhance its commercial capabilities and expand its market reach, contributing to its earnings. Additionally, the company invests in the research and development of new biosimilar candidates to sustain its growth and competitive position in the biopharmaceutical sector.

Coherus Biosciences Financial Statement Overview

Summary

Coherus Biosciences faces substantial financial challenges with declining revenues, persistent losses, and high leverage. The negative equity position and reliance on financing highlight potential risks. Improvement in operational performance and financial stability is critical for future growth.

Income Statement

The income statement reveals significant challenges for Coherus Biosciences, with declining revenue and consistent net losses over the periods. The TTM data shows negative margins across gross profit, EBIT, and EBITDA, indicating profitability issues. Revenue growth is negative, reflecting a downward trend in sales.

Balance Sheet

The balance sheet indicates high financial leverage with a negative stockholders' equity, suggesting insolvency risks. The debt-to-equity ratio is not calculable due to negative equity, and the equity ratio is negative, underscoring financial instability. Overall, the balance sheet reflects potential risks due to high liabilities.

Cash Flow

Cash flow analysis shows limited operational cash generation with a marginally positive free cash flow in the TTM period. However, historical data reflects negative operating and free cash flows, indicating reliance on external financing. The operating cash flow to net income ratio is unfavorable, suggesting inefficiencies in cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	197.50M	266.96M	257.24M	211.04M	326.55M	475.82M
Gross Profit	109.66M	149.41M	94.46M	140.96M	268.96M	438.16M
EBITDA	-98.76M	60.94M	-193.94M	-255.58M	-260.69M	161.84M
Net Income	-130.94M	28.51M	-237.89M	-326.63M	-306.32M	132.24M
Balance Sheet
Total Assets	371.07M	448.53M	629.60M	480.85M	679.33M	841.65M
Cash, Cash Equivalents and Short-Term Investments	82.41M	125.99M	117.75M	191.68M	417.19M	541.16M
Total Debt	231.42M	269.90M	480.84M	471.06M	408.28M	404.02M
Total Liabilities	554.54M	580.52M	823.03M	618.26M	581.61M	560.67M
Stockholders Equity	-183.47M	-131.99M	-193.43M	-137.42M	97.73M	280.97M
Cash Flow
Free Cash Flow	500.00K	-20.44M	-175.17M	-243.16M	-38.72M	147.09M
Operating Cash Flow	500.00K	-20.44M	-174.88M	-241.12M	-37.43M	154.15M
Investing Cash Flow	10.07M	230.32M	144.64M	-166.85M	-138.41M	-14.40M
Financing Cash Flow	-188.13M	-186.97M	69.60M	54.33M	51.88M	223.95M

Coherus Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRS, the sentiment is Negative. The current price of 0.76 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.86, and below the 200-day MA of 1.05, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.28 is Neutral, neither overbought nor oversold. The STOCH value of 46.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CHRS.

Coherus Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	46 Neutral	C$192.85M	-4.25	-8.56%	2.91%	13.52%	-1.74%
CHRS	45 Neutral	$86.15M	5.55	0.51%	―	-34.58%	-62.19%
GNLX	45 Neutral	$106.79M	―	-131.36%	―	-100.00%	9.16%
SLS	43 Neutral	$207.54M	―	-144.90%	―	―	60.51%
NAUT	41 Neutral	$92.09M	―	-30.93%	―	―	-1.20%
TIL	34 Underperform	$143.86M	―	-44.50%	―	―	52.54%

Coherus Biosciences Corporate Events

Coherus Biosciences Holds Virtual Annual Stockholder Meeting

On June 11, 2025, Coherus Oncology, Inc. held its Annual Meeting of Stockholders virtually, where various proposals were voted on. The stockholders elected three Class II directors, ratified Ernst & Young LLP as the company’s accounting firm, approved executive compensation, and amended the 2014 Employee Stock Purchase Plan.

The most recent analyst rating on (CHRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Coherus Biosciences Rebrands to Coherus Oncology

On May 29, 2025, Coherus BioSciences, Inc. changed its name to Coherus Oncology, Inc. to better align with its focus on innovative cancer therapeutics. This strategic transformation underscores the company’s commitment to advancing its oncology pipeline, including FDA-approved treatments and promising candidates in clinical trials, aiming to set new standards in cancer care and improve patient outcomes.

The most recent analyst rating on (CHRS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Coherus Biosciences stock, see the CHRS Stock Forecast page.

Coherus Biosciences Board Member Stolper Steps Down

On April 22, 2025, Mark D. Stolper, a member of the Board of Directors at Coherus BioSciences, announced his decision not to stand for re-election at the company’s 2025 Annual Meeting of Stockholders. His departure is not due to any disagreements with the company, and he will continue to serve in a consulting role until the end of 2026. Following his decision, the board will reduce its size to nine directors. To ensure balanced representation among the board’s classes, on April 23, 2025, Rita A. Karachun and Michael Ryan were reclassified to different board classes, maintaining uninterrupted service while complying with the company’s Certificate of Incorporation.

Coherus Biosciences CCO Resigns After UDENYCA Divestiture

Paul Reider, Coherus BioSciences’ Chief Commercial Officer, resigned effective April 30, 2025, following the company’s divestiture of its UDENYCA franchise. His departure is amicable, with no disagreements cited, and he will receive a compensation package including salary continuation and stock option extensions, while advising the company part-time until April 2026.

Coherus Biosciences Completes UDENYCA Franchise Divestiture

On April 14, 2025, Coherus BioSciences announced the completion of its UDENYCA franchise divestiture to Intas Pharmaceuticals for up to $558.4 million. This strategic move, which included an upfront payment of $483.4 million, allows Coherus to focus on its oncology programs, reduce debt, and extend its cash runway into 2027, thereby strengthening its market position and operational focus on novel cancer therapies.